image description  

A Phase 4 randomised study to assess the tolerability of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Liberia

  • 2010/01/01
Type de publication
  • Posters
  • Birgit Schramm
  • Parastou Valeh
  • Elisabeth Baudin
  • Charles S. Mazinda
  • Richard Smith
  • Loretxu Pinoges
  • Timothy Sundaygar
  • Yah M. Zolia
  • Joel J. Jones
  • Eric Comte
  • Vincent Jullien
  • Gwenaelle Carn
  • Jean-René Kiechel
  • Elizabeth A. Ashley
  • Philippe J. Guerin
  • Paludisme

Principal Objective
- To describe the clinical tolerability of ASAQ in > 5 years age group with uncomplicated P. falciparum malaria
compared to another well known ACT, artemether-lumefantrine (AL) Coartem®, in a highly endemic setting
Secondary Objectives
- To assess efficacy of the treatment at 28 days (PCR genotyping adjusted)
- To describe day 0 and day 7 blood levels of desethyl-amodiaquine and lumefantrine